Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele)

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3059-3064

  Moisan, J ^a   Wojciechowski, W ^a   Guilbault, C ^a   Lachance, C ^a   Di Marco, S ^a   Skamene, E ^a   Matlashewski, G ^a   Radzioch, D ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; GENE PRODUCT; NITRIC OXIDE; PROTEIN NRAMP1; RESIQUIMOD; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL KILLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GENE EXPRESSION; GENE LOCUS; GENE MAPPING; HERPES SIMPLEX VIRUS; HOST RESISTANCE; IMMUNOMODULATION; LEISHMANIA DONOVANI; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; WART VIRUS;

ALLELES; ANIMALS; CATION TRANSPORT PROTEINS; CELL LINE; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MICROBIAL; GENE EXPRESSION REGULATION, BACTERIAL; IMIDAZOLES; MACROPHAGES; MICE; MICE, KNOCKOUT; MYCOBACTERIUM BOVIS; MYCOBACTERIUM INFECTIONS; NITRIC OXIDE; SPLEEN;

EID: 0034769807     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3059-3064.2001     Document Type: Article

References (52)

1. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848
2. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (imiquimod) in genital warts
3. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%
4. Nramp1 locus encodes a 65 kDa interferon-gamma-inducible protein in murine macrophages
5. Nitrite production by macrophages derived from BCG-resistant and -susceptible congenic mouse strains in response to IFN-gamma and infection with BCG
6. I-A beta gene expression regulation in macrophages derived from mice susceptible or resistant to infection with M. bovis BCG
7. The natural resistance-associated macrophage protein and susceptibility to intracellular pathogens
8. Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections
9. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs
10. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
11. Treatment of genital warts with an immune-response modifier (imiquimod)
12. Genetic regulation of macrophage activation: Understanding the function of Nramp1 (=Ity/Lsh/Bcg)
13. The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6
14. Genetic control of natural resistance to Leishmania donovani
15. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action
16. Identification of genes induced by a macrophage activator, s-28463, using gene expression array analysis
17. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells
18. The Nramp1 protein and its role in resistance to infection and macrophage function
19. Self-administered topical 5% imiquimod cream for external anogenital warts
20. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609
21. Cellspecific and inducible Nramp1 gene expression in mouse macrophages in vitro and in vivo
22. Natural resistance to infection with intracellular pathogens: The Nramp1 protein is recruited to the membrane of the phagosome
23. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
24. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs
25. Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs
26. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463
27. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient
28. In vivo and In vitro interferon induction in chickens by S-28828, an imidazoquinolinamine immunoenhancer
29. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression
30. Nramp1 transfaction transfers Ity/Lsh/Bcg-related pleiotropic effects on macrophage activation: Influence on antigen processing and presentation
31. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways
32. Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod
33. Functional complementation of the yeast divalent cation transporter family SMF by NRAMP2, a member of the mammalian natural resistance-associated macrophage protein family
34. Molecular mechanisms of natural resistance to mycobacterial infections
35. Cytokine induction in mice by the immunomodulator imiquimod
36. Molecular genetics of inherited susceptibility to intracellular parasites
37. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine
38. The Bcg gene story
39. Cytokine induction and modifying the immune response to human papilloma virus with imiquimod
40. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells
41. Management of female genital warts with an analog of imiquimod 2% in cream: A randomized, double-blind, placebo-controlled study
42. Cytokine induction by the immunomodulators imiquimod and S-27609
43. Acquired resistance but not innate resistance to Mycobacterium bovis bacillus Calmette-Guerin is compromised by interleukin-12 ablation
44. Immunomodulating and antiviral activities of the imidazoquinoline S-28463
45. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes
46. Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN
47. Natural resistance to infection with intracellular parasites: Molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus
48. The Ity/Lsh/Bcg locus: Natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene
49. Natural resistance to intracellular infections: Nramp1 encodes a membrane phosphoglycoprotein absent in macrophages from susceptible (Nramp1 D169) mouse strains
50. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod
51. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro
52. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on the Nramp1 gene